ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
MRC Technology, the commercialization agent for the U.K. Medical Research Council, has licensed to Genentech several small-molecule drug candidates for the treatment of neurological diseases. MRC gets an up-front payment and could receive milestones as compound development progresses. The Genentech deal is the first major small-molecule pact to emerge from MRC Technology’s year-old Center for Therapeutics Discovery. And the deal is MRC’s second with industry this month: AstraZeneca and MRC recently agreed to screen their combined compound libraries against 10 biological targets (C&EN, July 12, page 20).
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter